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Abstract
Host cell factors can either positively or negatively regulate the assembly and egress of HIV-1 particles from infected cells.
Recent reports have identified a previously uncharacterized transmembrane protein, tetherin/CD317/BST-2, as a crucial host
restriction factor that acts during a late budding step in HIV-1 replication by inhibiting viral particle release. Although
tetherin has been shown to promote the retention of nascent viral particles on the host cell surface, the precise molecular
mechanisms that occur during and after these tethering events remain largely unknown. We here report that a RING-type E3
ubiquitin ligase, BCA2 (Breast cancer-associated gene 2; also called Rabring7, ZNF364 or RNF115), is a novel tetherin-
interacting host protein that facilitates the restriction of HIV-1 particle production in tetherin-positive cells. The expression
of human BCA2 in ‘‘tetherin-positive’’ HeLa, but not in ‘‘tetherin-negative’’ HOS cells, resulted in a strong restriction of HIV-1
particle production. Upon the expression of tetherin in HOS cells, BCA2 was capable of inhibiting viral particle production as
in HeLa cells. The targeted depletion of endogenous BCA2 by RNA interference (RNAi) in HeLa cells reduced the intracellular
accumulation of viral particles, which were nevertheless retained on the plasma membrane. BCA2 was also found to
facilitate the internalization of HIV-1 virions into CD63
+ intracellular vesicles leading to their lysosomal degradation. These
results indicate that BCA2 accelerates the internalization and degradation of viral particles following their tethering to the
cell surface and is a co-factor or enhancer for the tetherin-dependent restriction of HIV-1 release from infected cells.
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Introduction
The human immunodeficiency virus (HIV) exploits the host cell
machinery to maximize viral particle production [1]. In contrast,
there are multiple systems in host cells that render them resistant
to viral infection through the actions of innate host cell restriction
factors [2,3]. This intracellular innate system can in turn be
antagonized by certain viral proteins, creating a conflict between
host cells and pathogens. There is accumulating evidence to now
suggest that the balance between host and viral factors influences
the susceptibility of the host cells to HIV infection and ultimately
AIDS progression [4].
A human transmembrane protein, tetherin (also known as BST-
2, CD317 or HM1.24) has been identified as an interferon-
induced antiviral host factor in HIV-1-infected cells. During the
late phase of the viral replication pathway, tetherin retains nascent
HIV-1 virions at the plasma membrane and prevents viral spread
[5–7]. Tetherin has been shown not only to block the release of
lentiviruses such as HIV-1 or SIV, but also other viruses such as
MLV, HTLV-1, Lassa virus and the Marburg virus [8–10]. These
results indicate that tetherin has broad antiviral properties through
the inhibition of viral particle release, and therefore that the
activation of this protein might be an effective strategy as an anti-
viral therapy.
Viral Protein U (Vpu) is a 16 kD phosphoprotein that is
encoded almost exclusively by SIVCPZ and its descendants,
including HIV-1 [11–13]. Vpu is a factor that facilitates viral
particle release by antagonizing tetherin-mediated viral restriction
[6,7,14,15], in addition to its effects upon CD4 degradation
[16–18]. The expression of Vpu has been shown to downregulate
the tetherin levels on the plasma membrane resulting in effective
virion release [7,19]. Indeed, Vpu-defective HIV-1 virions are
efficiently retained on the plasma membrane and fewer viral
particles are released compared with wild-type virions in tetherin-
positive cells, including T cells and macrophages. [14,20]. On the
other hand, in tetherin-negative cells, viral particle release is much
less affected by either the presence or absence of Vpu [6,7]. These
results suggest that Vpu antagonizes the function of tetherin,
which otherwise restricts the release of HIV-1 from infected host
cells. Following cell surface tethering, HIV-1 virions are subjected
to internalization into CD63-positive endosomal compartments,
thereby limiting the extent of virus spread [6,15,21–25]. Although
tetherin can hold nascent viral particles on the cell surface of the
host cells, the precise molecular events following the virion
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processes remain largely unknown.
In our current study, we identify a RING-type E3 ubiquitin
ligase, BCA2 (breast cancer associated gene 2; identical to
Rabring7, ZNF364 or RNF115) as a novel tetherin-interacting
protein that enhances tetherin-dependent viral restriction. BCA2
was found to facilitate the internalization of HIV-1 particles
captured by tetherin on the plasma membrane by associating with
the cytoplasmic tail of tetherin and directing the degradation of
viral particles in lysosomes. Significantly, the targeted depletion of
BCA2 was found to reduce the intracellular accumulation of viral
particles and to increase the persistence of nascent virions on the
plasma membrane. Our current results thus reveal that BCA2 is a
potential antiviral host factor through its collaboration with
tetherin and is therefore a potential new therapeutic target for
AIDS and its related disorders.
Results
Identification of BCA2 as a tetherin-interacting protein
The precise mechanism in which HIV-1 particles undergo
internalization and/or degradation in cells following tetherin-
mediated capture on the plasma membrane has not been well
characterized. However, accumulating evidence now suggests that
plasma membrane-tethered virions transit the small G protein
Rab-dependent endocytotic pathway [6,15]. To delineate the
molecular determinants that regulate this process, we attempted to
identify the Rab family member or its effector proteins that
functionally interact with tetherin. As our initial screening test, we
performed immunoprecipitation and GST-pull down analyses to
examine the interaction of approximately 60 Rab family proteins
with either tetherin or HIV-1 Gag protein. These in vitro
interaction assays revealed that a Rab7-interacting protein, BCA2,
could interact with tetherin (data not shown). To further confirm
this interaction, we performed GST-pull down analysis with
recombinant GST-BCA2. 293T cells were transfected with either
N-terminal Myc-epitope-tagged wild-type tetherin or its deletion
mutant devoid of the cytoplasmic tail domain (tetherinD1–20).
Cell lysates were then subjected to GST-pull down analysis with
either GST alone or GST-BCA2. Consequently, GST-BCA2 was
found to interact with full-length tetherin in cell lysates, but to
interact less efficiently with tetherinD1–20 (Fig. 1A). This result
was further confirmed by immunoprecipitation analysis using
293T cells transfected with either Myc-tetherin or Myc-tether-
inD1–20 together with an N-terminal HA-tagged BCA2 construct
(Fig. 1B).
BCA2 contains an N-terminal Rab7 binding domain and a
C-terminal RING domain [26]. To investigate which of these is
involved in the interaction with tetherin, we constructed BCA2
derivatives lacking these domains for use in immunoprecipita-
tion analysis. Our results demonstrated that Myc-tetherin is
efficiently coimmunoprecipitated with the full length BCA2, the
N-terminal truncation mutant, BCA2DN (148–305 aa) or the
RING domain deleted mutant, BCA2DRING (1–227 aa)
(Fig. 1C). However, the C-terminal truncation mutant,
BCA2DC (1–147 aa), showed no detectable interaction with
Myc-tetherin (Fig. 1C). These results suggest that tetherin can
interact with the middle portion of BCA2 (147–227 aa) located
between the Rab-interacting domain and RING finger domain.
We also confirmed an interaction between endogenous BCA2
and tetherin in HeLa cells (Fig. 1D), where these proteins were
verified to be endogenously expressed (Fig. S1).
To further verify the association between BCA2 and tetherin in
cells, we examined the intracellular localization of these two
proteins using confocal microscopy. Immunofluorescent analysis
revealed that N-terminal GFP-tagged tetherin and HA-BCA2
show a similar distribution in cells and form multiple cytoplasmic
dots when they are expressed alone (Fig. 1E). When GFP-tetherin
and HA-BCA2 are co-transfected however, these proteins show a
significant co-localization predominantly in the cytoplasm, but also
in part at the plasma membrane (Fig. 1E). These results together
indicate that BCA2 is a tetherin-interacting protein that associates
with the cytoplasmic tail of tetherin in cells.
BCA2 facilitates the restriction of HIV-1 particle
production in cells expressing tetherin
We next examined the effects of BCA2 upon HIV-1 particle
production in both endogenously tetherin-positive HeLa cells and
in tetherin-negative HOS cells. Endogenous tetherin expression on
the cell surface was confirmed by flow cytometric analysis (Fig.
S1A). Cells were transfected with different amounts of HA-BCA2
together with either the HIV-1 proviral plasmid (pNL4–3) [27] or
a Vpu-deleted version of this construct (pNL4–3DVpu) [14]. After
48 hours, cell supernatants were assayed for the Gag p24 antigen.
Strikingly, the expression of BCA2 in tetherin-positive HeLa cells
led to a strong restriction of HIV-1 particle production.
Importantly, the restriction of Vpu-deleted HIV-1 was more
prominent than that of the WT virus in HeLa cells (Fig. 2A).
However, there was no significant suppressive effect of BCA2 on
viral particle production in tetherin-negative HOS cells (Fig. 2A).
This indicated that BCA2 reduces HIV-1 particle production in
the presence of tetherin. Consistent with this observation, HOS
cells exogenously expressing relatively low amounts of tetherin, but
not the tetherinD1–20 mutant, showed BCA2-mediated restriction
of HIV-1 particle production (Fig. 2B).
Since Vpu has been shown to antagonize the antiviral activity of
tetherin [6,7], we next investigated whether Vpu could also
counteract the antiviral effects of BCA2. As expected, Vpu-
defective HIV-1 particle production was almost completely
recovered by the expression of Vpu in HeLa cells (Fig. 2C).
However, the co-expression of BCA2 significantly suppressed the
recovery of virus particle production by Vpu (Fig. 2C). Conversely,
the expression of a truncated Vpu mutant (Vpu1–50), the function
of which is partly impaired [6], only partially counteracted HIV-1
Author Summary
Human cells possess multiple systems that render them
resistant to viral infection. Recently, a transmembrane
protein, tetherin, has been identified as an antiviral host
factor in HIV-1-infected cells. Tetherin retains newly
assembled virions at the plasma membrane and prevents
viral release from the infected cells. However, the precise
molecular mechanisms following the virion tethering
remain largely unknown. In our current study, we have
identified a RING-type E3 ubiquitin ligase, BCA2, which co-
localizes and interacts with tetherin in human cells. BCA2
was found to facilitate the internalization of HIV-1 particles
captured by tetherin on the plasma membrane and to
enhance the targeting of viral particles to the lysosomes.
Conversely, the targeted depletion of endogenous BCA2
reduces the intracellular accumulation of viral particles.
Additionally, the expression of a small viral protein Vpu, an
antagonist of tetherin, counteracts the antiviral effects of
BCA2. These results suggest that BCA2 is a potential
antiviral factor that collaborates with tetherin to facilitate
the degradation of nascent HIV-1 particles during ‘‘post-
tethering’’ processes.
A Functional Interactor of Tetherin
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functional Vpu antagonizes the restrictive activity of BCA2.
Together with our finding that BCA2 can restrict HIV-1 particle
production only in tetherin-expressing cells, these data indicate
that the function of tetherin, which is antagonized by Vpu, is likely
required for the BCA2-mediated restriction of HIV-1 particle
production.
Previous studies have demonstrated that BCA2 has E3 ubiquitin
ligase activity which is essential for the downregulation of EGFR
expression [28]. We therefore examined whether this activity is
necessary for the anti-viral effects of BCA2. We created a RING
finger-defective mutant BCA2 (C228A/C231A) [29] and investi-
gated its effect upon virus particle production. Although a tetherin-
interacting motif defective BCA2 mutant (BCA2DC) failed to
restrict viral particle production, both WT and C228A/C231A
BCA2 were capable of doing so (Fig. 2D). Moreover, the effect of
C228A/C231A BCA2 mutant was modest increase than that of
WT BCA2 (Fig. 2D), probably due to the inhibition of both auto-
ubiquitination and following degradation of this mutant as
reported previously [28]. These results indicate that the ubiquitin
ligase activity of BCA2 is dispensable for its function in the
restriction of virus particle formation.
To next investigate the effects of BCA2 upon virus particle
restriction in T cells, we created Jurkat cells stably expressing
untagged BCA2 (Fig. 2E). FACS analysis with a tetherin
antibody revealed that these cells indeed express tetherin on
their cell surface (Fig. S1A). The cells were then infected with
either HIV-1NL4–3 or HIV-1NL4–3DVpu at a low multiplicity of
infection (m.o.i.=0.05). In agreement with a previous report
[11], we found that Vpu-deleted virus replicated slightly less
efficiently than WT-virus (Fig. 2E). Our results showed that
BCA2 expression reduces HIV-1 particle production in both
WT- and DVpu-virus infected cells, although this effect was
more prominent in cells infected with DVpu-virus (about 4-fold)
than with WT-virus (about 2-fold) (Fig. 2E). Interestingly,
immunoblotting analysis revealed that the expression levels of
endogenous BCA2 in HeLa and Jurkat cells were relatively
lower than in HOS cells (Fig. S1B), implying that exogenous
BCA2 expression would tend to impact virus particle restriction
in these cells in the presence of functional tetherin.
To delineate the molecular mechanism by which BCA2
suppresses virus production, we performed immunoblotting
analysis with a p24 antibody. Interestingly, the expression of
BCA2 in HeLa cells significantly reduced the Gag protein
Figure 1. BCA2 is a tetherin-interacting protein. (A) GST pull-down analysis of 293T cells expressing either N-terminally Myc-tagged-tetherin
(FL) or a mutant lacking the cytoplasmic tail domain (D1–20). Cell lysates were precipitated with either purified GST or GST-BCA2, followed by
immunoblotting analysis with a Myc antibody to detect BCA2 binding (top panels). To control for the expression levels of GST, a Coomassie Brilliant
Blue stained image is also shown (bottom panel). (B) Immunoprecipitation analysis of 293T cells expressing N-terminally HA-tagged-BCA2 together
with either Myc-tetherin (FL) or its mutant (D1–20). Cell lysates were immunoprecipitated with HA antibodies, followed by immunoblotting analysis
with either HA or Myc antibodies. (C) Immunoprecipitation analysis of 293T cells expressing Myc-tetherin together with HA-BCA2 (FL) or its deletion
mutants (DRING, DC and DN). Asterisks indicate non-specific IgG bands. (D) Immunoprecipitation analysis of endogenous tetherin and BCA2. HeLa
cell lysates were immunoprecipitated with either anti-tetherin monoclonal antibody or control mouse IgG followed by immunoblotting with the
indicated antibodies. (E) Confocal microscopic analysis of HeLa cells expressing GFP-tagged tetherin and HA-BCA2 (scale bar, 10 mm). Cells were fixed,
permeabilized and stained with HA antibodies (red) followed by confocal microscopy. The inset shows an expanded view of the area indicated by the
white box in which an association of GFP-tetherin with HA-BCA2 at the plasma membrane is evident.
doi:10.1371/journal.ppat.1000700.g001
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PLoS Pathogens | www.plospathogens.org 3 December 2009 | Volume 5 | Issue 12 | e1000700Figure 2. BCA2 inhibits HIV-1 particle production in cells expressing tetherin. (A) Single-round virus release analysis was performed
using the indicated cell types transfected with either 300 ng of pNL4–3 or pNL4–3DVpu along with the indicated amounts of pCMV-HA-BCA2. At
48 hours following transfection, cell supernatants were analyzed by p24 ELISA. Immunoblotting with a BCA2 antibody for both endogenous and
HA-tagged BCA2 expression is shown in the bottom panels. (B) Tetherin-dependent effects of BCA2 on HIV-1 particle production. HOS cells were
transiently transfected with 100 ng of pCMV-Myc-tetherin or its deletion mutant (D1–20, lacking the cytoplasmic tail) together with 300 ng of pNL4–3
and indicated amounts of pCMV-HA-BCA2, followed by p24 ELISA. (C) Vpu antagonizes the effects of BCA2 upon HIV-1 particle production. HeLa cells
were transiently transfected with either the indicated amounts of Vpu or its deletion mutant (1–50, lacking a portion of the cytoplasmic domain) and
300 ng of pNL4–3DVpu was co-transfected with or without 300 ng of pCMV-HA-BCA2. After 48 hours, cell supernatants were analyzed by p24 ELISA.
(D) Single-round virus release analysis was performed using HeLa cell transfected with 300 ng of pNL4–3 along with either pCMV-HA-BCA2 (WT), its
RING finger-defective mutant (C228A/C231A) or tetherin-interacting motif defective BCA2 mutant (DC). At 48 hours following transfection, viral
supernatants were analyzed by p24 ELISA. (E) Jurkat cells were transfected with either empty vector (EV) or pIRESpuro-BCA2 by electroporation and
selected with puromycin for 24 hours. The stable expression of BCA2 on Jurkat cells was confirmed by BCA2 immunoblotting (top panel). Cells were
then infected with either HIV-1NL4–3 or HIV-1NL4–3DVpu at a low multiplicity. Cell supernatants were harvested at the indicated time-points and
subjected to p24 ELISA (bottom panel). (F) BCA2 reduces the level of cell-associated Gag protein. Immunoblotting analysis of the cell lysates
described in (A) was performed. The numerical values below the blots indicate the Gag signal intensities determined by densitometry. The virus
release efficiency was calculated as ‘‘Sup Gag per Total Gag (Cell Gag plus Sup Gag)’’. (G) Pulse-chase analysis of HeLa cells transfected with
pNL4–3DVpu together with either control vector or pCMV-HA-BCA2. Two days after transfection, the radiolabeled cells were harvested at the
indicated times, and cell lysates were immunoprecipitated with anti-p24 antibody, and then analyzed by SDS-PAGE and autoradiography (left panel).
The relative intensity of Gag bands was determined by densitometry (right panel).
doi:10.1371/journal.ppat.1000700.g002
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the expression of Vpu (Fig. 2F). Our results also indicate that
BCA2 expression has modest effects on viral release efficiency
as compared with its drastic effects on the cell-associated p24
protein levels (Fig. 2F). Of note, the BCA2-induced depletion
of cell-associated p24 in the absence of Vpu was more
prominent than in the presence of Vpu (Fig. 2F). These data
together suggest that BCA2 may enhance the degradation of
nascent HIV-1 virions captured by tetherin on the plasma
membrane.
To rule out the possibility that BCA2 affects the expression of
HIV-1 proteins, we next performed pulse-chase analysis with
pNL4-3DVpu-transfected HeLa cells. Our results demonstrated
that BCA2 expression induces the rapid degradation of the
HIV-1 Gag protein (Fig. 2G). Consistent with our immuno-
blotting data (Fig. 2F), the degradation of p24 was shown to be
more prominent than that of Pr55 (Fig. 2G). Furthermore, our
RT-PCR analysis revealed that BCA2 expression does not
significantly affect the mRNA levels of HIV-1 Gag (Fig. S2).
These results together indicate that BCA2 facilitates the
intracellular degradation of virus particles rather than the
s u p p r e s s i o no fH I V - 1p r o t e i ne x p r e s s i o n .
BCA2 promotes the accumulation of HIV-1 virions in
intracellular compartments
As described above, the expression of BCA2 significantly
reduces the level of cell-associated p24 protein, raising the
possibility that it facilitates the intracellular degradation of
unreleased virions. To test this possibility, we performed
transmission electron microscopy (TEM) analysis of HeLa cells
transduced with proviral plasmid together with either HA-BCA2
or a control vector. In control cells, nascent assembled virions were
observed on the plasma membrane and relatively little accumu-
lation of virions was observed in intracellular compartments
(Fig. 3A). In BCA2-expressing cells, however, substantial numbers
of mature virions could be observed in the intracellular vesicles,
and a significant reduction of mature viral particles on the plasma
membrane was found (Fig. 3B). This suggests that BCA2 facilitates
the internalization of mature viral particles into intracellular
vesicles for degradation.
BCA2 enhances the targeting of HIV-1 virions for
lysosomal degradation
Consistent with our TEM results, immunofluorescent and
confocal microscopic analysis further revealed that BCA2
expression promotes the accumulation of p24 in CD63
+
intracellular compartments when compared with the vector
control (Figs. 4A, B). Various proteins that are sorted into
CD63
+ intracellular compartments are destined for lysosomal
degradation [30,31]. To address whether virion degradation is
mediated by this pathway following internalization, we co-
transfected HeLa cells with the HIV-1 proviral plasmid
together with either empty vector or HA-BCA2, and then
treated the cells with lysosome inhibitors (leupeptin and
NH4Cl). Strikingly, treatment with lysosome inhibitors signif-
icantly blocked the decrease in intracellular Gag in BCA2-
expressing cells (Fig. 4C). Importantly also, parallel ELISA
analysis of the supernatants from these transduced cells
revealed that lysosome inhibitors had no effect upon viral
release (Fig. 4D). These results suggest that BCA2 promotes
the lysosomal degradation of HIV-1 virions following their
retention on the plasma membrane and subsequent internal-
ization into CD63
+ endosomes.
The targeted depletion of BCA2 reduces the intracellular
accumulation of HIV-1 particles
To further delineate the role of endogenous BCA2 in HIV-1
particle release, we next performed experiments in which HeLa
cells were transduced with either control or two different BCA2-
specific siRNAs (BCA2-I, II) and then transfected with pNL4-3 or
Figure 3. BCA2 promotes the accumulation of HIV-1 virions in
intracellular compartments. Electron microscopic analysis of HeLa
cells transfected with pNL4–3 and either control vector (A) or pCMV-HA-
BCA2 (B), at a molar ratio of 1:3. (Scale bars, 1 mm except where
indicated).
doi:10.1371/journal.ppat.1000700.g003
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demonstrated that both of the siRNAs targeting BCA2 could
significantly reduce its endogenous expression (Fig. 5A). Measure-
ment of the p24 antigen levels in the cell supernatant further
revealed that viral particle production was only slightly increased
in both pNL4–3 and pNL4–3DVpu transfected cells, although the
effect was more significant in pNL4–3DVpu transfected cells
(approximately 2-fold) (Fig. 5A).
Immunofluorescent analysis by confocal microscopy addition-
ally revealed that although the localization of Gag proteins was
observed predominantly in CD63
+ intracellular structures in
control-siRNA treated cells, this profile was dramatically shifted to
the plasma membrane in BCA2-siRNA treated cells (Figs. 5B, C).
This indicated that the silencing of BCA2 blocks the relocation of
virions into the intracellular compartments and increases the
persistence of virions captured by tetherin on the cell surface.
To further investigate this possibility, siRNA-transduced cells
were subsequently treated with the protease subtilisin, which
liberates cell surface-captured virions by abolishing virion-tetherin
interactions [15]. In the case of WT-virus, subtilisin stripping had
only slight effects upon virion release (Fig. 5D), in agreement with
a previous report [15]. However, in the case of Vpu-defective
virus, viral release from BCA2-deplation cells was significantly
recovered by subtilisin stripping, reaching the level of WT-virus
infected cells (Fig. 5D). These data suggest that BCA2 depletion
inhibits the intracellular accumulation of Gag proteins and,
consequently, increases the fraction of virions retained at the cell
surface by tetherin.
Overall, the results of our current study indicate that BCA2
facilitates the internalization of HIV-1 virions that have not been
released, thereby enhancing their degradation. This internaliza-
tion and degradation of cell surface-retained virions may represent
rate limiting steps in the tetherin-mediated restriction of viral
release that are accelerated by BCA2.
Discussion
In our current study, we identify BCA2 as a functional tetherin-
interacting protein. Although BCA2 is widely expressed in various
cell lines [26,32], its antiviral effects have been observed only in cells
expressing tetherin, suggesting that BCA2 cooperates with tetherin
to achieve efficient restriction of viral particle production. BCA2
Figure 4. BCA2 enhances HIV-1 virion trafficking to lysosomes. (A) Confocal microscopic analysis of HeLa cells expressing pNL4–3 and either
empty vector (top row) or pCMV-HA-BCA2 (bottom row), at a molar ratio of 1:3 (scale bar, 10 mm). Note that these transfected cells also expressed
Vpu. Cells were stained with anti-p24 (green) and anti-CD63 (red) antibodies and analyzed by confocal microscopy. (B) In the cultures described in (A),
over 100 cells were analyzed for the subcellular localization of p24, which was either strongly evident at the plasma membrane (PM only), or
intracellular accumulations as well as at the plasma membrane (Int + PM). The data are given as a percentage of the total cells. (C, D) HeLa cells
transfected with 300 ng of pNL4–3 and either empty vector or pCMV-HA-BCA2, at a molar ratio of 1:3, were treated with or without lysosomal
inhibitors. Inhibitors were added to the medium 18 hours before harvesting. Cell lysates and supernatants were then analyzed by immunoblotting (C)
and p24 ELISA (D). The final concentrations of leupeptin and NH4Cl were 5 mg/ml and 2 mM, respectively. The Gag signal intensities and the virus
release efficiency are shown below the blots, as in Fig. 2F.
doi:10.1371/journal.ppat.1000700.g004
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internalization and degradation of nascent HIV-1 virions, following
their tethering to the host cell plasma membrane. These
internalization and degradation steps may be rate limiting during
restriction by tetherin because the targeted depletion of BCA2 can
shift the distribution of Gag to the plasmamembrane and canpartly
overcome the release inhibition of Vpu-minus virions in HeLa cells.
Importantly in this regard, BCA2 directs HIV-1 particles to
CD63
+ endosomes or lysosomes for degradation. The molecular
mechanisms by which this is achieved have not yet been fully
characterized. However, previous studies have demonstrated that
BCA2 directly binds a small G protein, Rab7, and thereby plays
crucial roles in vesicle trafficking to the late endosomes or
lysosomes, in addition to lysosome biogenesis [26,33]. Indeed, the
aberrant expression of BCA2 not only affects epidermal growth
factor receptor (EFGR) degradation, but also induces the
perinuclear aggregation of lysosomes and increased acidity within
lysosomes [26,28]. Given our current data, these results indicate
that BCA2 coordinates the trafficking of intracellular vesicles
containing internalized viral particles to the lysosomes in
conjunction with Rab7, resulting in the effective degradation of
these virions. Consistently, in tetherin-positive HeLa cells, Gag
protein has been shown to co-localize with the GTP-bound active
form of Rab7 in the absence of Vpu (our unpublished
observation). Furthermore, a dominant negative mutant of Rab5
can inhibit the internalization of nascent HIV-1 particles [15].
These findings raise the possibility that plasma membrane-
tethered virions may go through a Rab5- and/or Rab7-dependent
endocytotic pathway from the cell surface to the endosomes or
lysosomes and eventual degradation. Notably, our immunopre-
cipitation data indicate that BCA2 interacts with tetherin at a
region distinct from the Rab7 binding site. Consistently, an N-
terminal truncation mutant of BCA2 can still interact with
tetherin. These results suggest that BCA2 may simultaneously
interact with Rab7 and tetherin at distinct regions and might
therefore act as a physical scaffolding protein between these two
proteins. During endocytosis, tetherin-BCA2 complexes might
therefore recruit Rab7 to vesicles containing virions.
Although the function of BCA2 during HIV-1 restriction is
likely to be dependent on tetherin, the antiviral effects of BCA2
were found to be still active against Vpu-positive viruses. However,
the overexpression of Vpu can abrogate the antiviral effects of
BCA2, indicating a potentially stoichiometric relationship between
BCA2 and Vpu during BCA2-mediated viral restriction. Impor-
tantly, our current results suggest that BCA2 is not involved in
regulating the expression of Vpu. However, it is possible that
BCA2 antagonizes the function of Vpu in counteracting tetherin,
although further analysis is needed to address this question.
Our current results additionally demonstrate that the effects of
BCA2 depletion on particle production are about two-fold, which
is a relatively modest impact compared with the 5-to-10-fold
effects of Vpu in tetherin-positive cells. This indicates that the
inhibition of BCA2 cannot fully restore Vpu-defective HIV-1
particle production to the level of the WT-virus. Apparently,
capture of virions on the plasma membrane by tetherin provides
restriction even when BCA2-depletion suppresses the internaliza-
tion and degradation of nascent virions. These effected were
further revealed by our subtilisin stripping assay; BCA2-depletion
plus subtilisin treatment recovered DVpu-virus particle production
to the level of the WT-virus. These results indicate that BCA2 very
likely functions downstream of virus tethering on the plasma
membrane (i.e. post-tethering stages).
In summary, the results of our current study demonstrate that
BCA2 is a potential anti-HIV-1 host factor that partners with
Figure 5. The targeted depletion of BCA2 blocks the
intracellular accumulation of viral particles. (A) Single-round
virus release analysis of HeLa cells treated with control siRNA or two
different BCA2-targeted siRNA vectors for 24 hours, prior to
transfection with pNL4–3 or pNL4–3DVpu. At 48 hours following
transfection, cell supernatants were analyzed by p24 ELISA. Immu-
noblotting analysis with a BCA2 antibody to detect endogenous BCA2
expression is shown in the bottom panel. (B) Confocal microscopic
analysis of HeLa cells treated with control siRNA (upper panels) or
BCA2-targeted siRNA (lower panels), prior to transfection with pNL4–
3DVpu (scale bar, 10 mm). After 48 hours following transfection, cells
were fixed and immunostained with anti-p24 (green) and anti-CD63
(red) antibodies followed by confocal microscopy. (C) In the cultures
described in (B), over 100 cells were analyzed for the subcellular
localization of p24, as described in Fig. 4B. (D) HeLa cells were treated
with control siRNA or BCA2-targeted siRNA for 24 hours, prior to
transfection with pNL4–3 or pNL4–3DVpu as in (A). At 48 hours
following transfection, cell supernatants were harvested (first
supernatants) and cells were treated with either PBS or buffer
containing the protease subtilisin (1 mg/ml) for 15 min, prior to
re-harvesting of the cell supernatants (second supernatants). Boththe
first and second supernatants were then mixed and analyzed by
p24 ELISA.
doi:10.1371/journal.ppat.1000700.g005
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viral particles. Our present findings thus shed new light on the
molecular machinery underlying the tetherin-dependent HIV-1
restriction pathway. BCA2 and other molecules of this pathway
may thus be potential new therapeutic targets for AIDS and its
related disorders.
Materials and Methods
Cells and transfections
HeLa, HOS and 293T cells were cultured in DMEM
supplemented with 10% fetal bovine serum (FBS). Jurkat cells
were maintained in RPMI-1640 containing 10% FBS. Plasmid
transfections into adherent or suspended cells were performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) or Amaxa
nucleofector (Program S-18; Amaxa biosystems, Cologne, Ger-
many), respectively, according to the manufacturer’s instructions.
Plasmids and viruses
Human BCA2 and tetherin/CD317 coding sequences were
amplified from HeLa total RNA by RT-PCR using the following
pairs of oligonucleotides containing restriction enzyme BamHI
sites (underlined) or a stop codon (boldface): 59-GGATCCGG-
ATGGCGGAGGCTTCGGCGGC-39 (BCA2 forward primer,
sense) and 59-TCAGAAAGTCCATCGGTCATG-39 (BCA2
reverse primer, antisense); 59-GGATCCGGATGGCATCTACT-
TCGTATGA-39 (tetherin forward primer, sense) and 59-TCA-
CTGCAGCAGAGCGCTGAGGC-39 (tetherin reverse primer,
antisense). The purified PCR products were inserted into the
pCR4Blunt-TOPO vector (Invitrogen), and cDNA inserts were
then subcloned into pCMV-HA, pCMV-Myc, pEGFP-C1,
pIRESpuro (Clontech, Palo Alto, CA) or pGEX-KG (Amersham
Bioscience, Sunnyvale, CA) vectors. A human codon-optimized
HIV-1 Vpu expression vector (pcDNA-Vphu) [34] and Vpu-
deleted HIV-1 molecular clone (pNL4–3/Udel, herein called
pNL4–3DVpu) [14] were kindly provided by Dr. K. Strebel
(National Institutes of Health, Bethesda, MD). The DRING (1–
227 aa), DN (148–305 aa), DC (1–147 aa), and C228A/C231A
derivatives of BCA2, the tetherin mutant D1–20 (21–180 aa) and
the truncated Vpu mutant (1–50 aa) were constructed using
standard molecular cloning procedures. The WT-virus or DVpu-
virus stocks were produced by transient transfection of 293T cells
with the pNL4–3 or pNL4–3DVpu proviral plasmids, respectively.
Culture supernatants containing virus were collected 48 hours
after transfection, filtered through a 0.45 mm Millex-HV filter
(Millipore, Billerica, MA) and immediately stored at 280uC
until use.
Antibodies
An anti-BCA2 polyclonal antibody was produced by UNI-
TECH (Chiba, Japan). An anti-p24 monoclonal antibody has been
described previously [35]. The rabbit anti-Vpu and mouse anti-
HM1.24 (tetherin) antibodies were kindly donated by Dr. K.
Strebel (National Institutes of Health, Bethesda, MD) [36] and
Chugai Pharmaceutical Co. (Kanagawa, Japan) [37], respectively.
Other antibodies used in this study were as follows: mouse anti-HA
(Roche, Basel, Switzerland), mouse anti-Myc (Roche), mouse anti-
a-tubulin (Sigma, St. Louis, MO), rabbit anti-CD63 (Santa Cruz
Biotechnology, Santa Cruz, CA) and Alexafluor-conjugated anti-
IgG (Invitrogen).
In vitro binding assays
For GST pull-down assays, GST-tagged BCA2 was expressed in
Escherichia coli BL21 (DE3) cells and purified using standard
protocols. Myc-tetherin-expressing 293T cell lysates were incu-
bated with glutathione-beads that had been coupled with GST-
BCA2 proteins. The beads were then washed, and bound proteins
were visualized by Coomassie Brilliant Blue R-250 staining and
analyzed by immunoblotting. For immunoprecipitation analysis,
293T cells expressing Myc-tetherin and HA-BCA2 were lysed and
incubated with an anti-HA affinity gel (Sigma). Alternatively, to
detect endogenous tetherin-BCA2 complexes, HeLa cell lysates
were co-incubated with protein A/G-mixed Sepharose (GE
Healthcare, UK) and either anti-tetherin antibody or control
mouse IgG. Bound proteins were analyzed by SDS-PAGE and
immunoblotting.
Single-round viral release and multi-cycle replication
assays
Cells in 12-well plates were co-transfected with pNL4–3 or
pNL4–3DVpu (300 ng) and either pCMV-HA-BCA2 or empty
vector (0–300 ng), in the presence or absence of vectors encoding
Vpu (30 or 75 ng) or Myc-tetherin (100 ng). Two days after
transfection, virus-containing supernatants were harvested and
filtrated to remove debris, and p24 antigens were measured by
Lumipulse (Fujirebio, Tokyo, Japan). For immunoblotting assays,
the virus-containing supernatants (400 ml) was layered onto 600 ml
of 20% sucrose in PBS and centrifuged at 20,000 g for 2 hours at
4uC. The cell lysates were prepared using RIPA buffer by
incubation at 4uC for 10 minutes and centrifugation at 16,000 g for
30 minutes. In experiments using lysosomal inhibitors, each drug
was added 18 hours before harvesting. Immunoblotting band
intensities were quantitated with ImageJ software.
For multi-cycle replication assays, Jurkat cells (1610
6) were
transfected with either empty vector or pIRESpuro-BCA2 (3 mg).
After the selection of transfectants with puromycin for 24 hours,
cell aliquots were then infected with either HIV-1NL4–3 or HIV-
1NL4–3DVpu at an m.o.i of 0.05. Viral supernatants were collected
periodically, and p24 levels were measured as described above.
Microscopy
One day prior to transfection, HeLa cells were seeded onto
glass-bottom dishes coated with poly-L-lysine (Matsunami, Osaka,
Japan). At 48 hours after transfection, the cells were fixed with 4%
paraformaldehyde and permeabilized with 1% Triton X-100.
Cells were than stained with primary antibodies and Alexa-
conjugated secondary antibodies. Confocal microscopic imaging
was performed using a Zeiss LSM510 instrument equipped with a
636oil-immersion objective. For electron microscopy, transfected
HeLa cells were fixed with 2.5% glutaraldehyde and subjected to
transmission electron microscopy, as described previously [38].
Pulse-chase radiolabeling
Cells in 6-well plates were co-transfected with pNL4–3DVpu
(1 mg) and either pCMV-HA-BCA2 or empty vector (3 mg). Two
days after transfection, the cells were washed and starved in Met-/
Cys-depletion medium (Invitrogen) for 30 min and pulse-labeled
for 15 min with 0.25 mCi/ml of [
35S]Met-Cys medium, and
chased in unlabeled medium for 4.5 hours. Cells were harvested
periodically, and cell lysates were immunoprecipitated with
anti-p24 antibody, and then analyzed by SDS-PAGE and
autoradiography.
siRNA knockdown and subtilisin stripping assays
BCA2-targeted siRNAs were obtained from Invitrogen as
Stealth Select RNAi constructs (Oligo ID #HSS120532 and
#HSS120534). A Stealth RNAi Luciferase reporter control
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well plates were transfected with these siRNAs at a final
concentration of 50 mM using Lipofectamine RNAiMAX (Invi-
trogen). The following day, the cells were re-transfected with
300 ng of either pNL4–3 or pNL4–3DVpu, and two days later
were harvested and analyzed by immunoblotting or confocal
microscopy.
For protease subtilisin stripping assays, viral supernatants
(1.2 ml) from siRNA/DNA-transfected HeLa cells were harvested
as a ‘‘first supernatant’’. After harvesting, the cells were washed
once with pre-warmed PBS and then incubated with 300 mlo f
either PBS or Tris/HCl (pH 8.0) buffer containing 1 mg/ml
subtilisin (Sigma) for 15 min at 37uC. To stop the reaction, 900 ml
of DMEM containing 5 mM PMSF were added to the cells, and
supernatants (total 1.2 ml) were again harvested as a ‘‘second
supernatant’’. Both the first and second supernatants were then
mixed and the p24 levels were measured as described above.
Accession numbers
The GenBank accession numbers for human BCA2 (Rabring7/
ZNF364/RNF115) and human tetherin (CD317/BST-2/
HM1.24) are BC054049 and D28137, respectively.
Supporting Information
Figure S1 Endogenous expression of tetherin and BCA2 in the
cells used in this study. (A) Flow cytometric analysis of cell surface
tetherin expression in HeLa, HOS and Jurkat cells. Cells were
washed with ice-cold PBS containing 1% BSA, and were blocked
for 10 min with 10% normal goat serum. The cells were then
stained with an anti-tetherin monoclonal antibody (0.1 mg/ml) and
a PE-conjugated secondary antibody (Beckman Coulter, Fullerton,
CA). All samples were analyzed with a FACS Caliber (BD
Biosciences, San Jose, CA). (B) Immunoblotting analysis of the
indicated cell lysates. Blots were probed with either anti-BCA2 or
anti-a-tubulin antibodies.
Found at: doi:10.1371/journal.ppat.1000700.s001 (0.20 MB PDF)
Figure S2 BCA2 has no detectable effects on the Gag RNA
levels. RT-PCR analysis of total RNA extracted from HeLa cells
transfected with pNL4–3 and either control vector or pCMV-HA-
BCA2 at a molar ratio of 1:1. The PCR primers were as follows:
59-CCCTATAGTGCAGAACCTCCA-39 (p24CA RT-forward)
and 59-CATTATGGTAGCTGGATTTGTTAC-39 (p24CA RT-
reverse); 59-GATCCGGTACTAGAGGAACTGAAAAAC-39 (Ex-
ogenous BCA2 RT-forward) and 59-TCACTGCAGCAGAG-
CGCTGAGGC-39 (Exogenous BCA2 RT-reverse); 59-ACG-
GATGGACTTTCTGAAGC-39 (Endogenous BCA2 RT-forward)
and 59-AAGGCAACATGACAGACAGC-39 (Endogenous BCA2
RT-reverse). The G3PDH RT-primers used have been described
previously [35]. To clarify the differences between exogenous and
endogenous BCA2, the exogenous BCA2 RT-forward primer
contains a vector-derived sequence. Numerical values below the
blots indicate the Gag signal intensities normalized to the G3PDH
values determined by densitometry.
Found at: doi:10.1371/journal.ppat.1000700.s002 (0.08 MB PDF)
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